| Company Name: |
Wuhan Topule Gold |
| Tel: |
+86-02787215551 19945035818 |
| Email: |
2936752263@qq.com |
- VE 822
-
-
2026-06-30
- CAS:1232416-25-9
- Min. Order: 1KG
- Purity: 98.0%
- Supply Ability: 10000KGS
- Berzosertib
-
- $30.00
-
2026-05-11
- CAS:1232416-25-9
- Purity: 99.61%
- Supply Ability: 10g
- VE 822
-
- $2.00
-
2019-07-06
- CAS:1232416-25-9
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 100kg
|
| Product Name: | VE 822 | | Synonyms: | VX970 (VE-822);2-Pyrazinamine, 3-[3-[4-[(methylamino)methyl]phenyl]-5-isoxazolyl]-5-[4-[(1-methylethyl)sulfonyl]phenyl]-;3-[3-[4-[(Methylamino)methyl]phenyl]-5-isoxazolyl]-5-[4-[(1-methylethyl)sulfonyl]phenyl]-2-pyrazinamine VE-822;VE 822 3-[3-[4-[(Methylamino)methyl]phenyl]-5-isoxazolyl]-5-[4-[(1-methylethyl)sulfonyl]phenyl]-2-pyrazinamine;VE 822;3-[3-[4-[(Methylamino)methyl]phenyl]-5-isoxazolyl]-5-[4-[(1-methylethyl)sulfonyl]phenyl]-2-pyrazinamine;VE822; VE 822;CS-1487 | | CAS: | 1232416-25-9 | | MF: | C24H25N5O3S | | MW: | 463.55 | | EINECS: | 1592732-453-0 | | Product Categories: | Inhibitors | | Mol File: | 1232416-25-9.mol |  |
| | VE 822 Chemical Properties |
| Melting point | >197°C (dec.) | | Boiling point | 674.4±55.0 °C(Predicted) | | density | 1.263±0.06 g/cm3(Predicted) | | storage temp. | Refrigerator | | solubility | DMSO (Slightly), Methanol (Slightly) | | pka | 8.88±0.10(Predicted) | | form | Solid | | color | Light Yellow | | InChIKey | JZCWLJDSIRUGIN-UHFFFAOYSA-N | | SMILES | C1(N)=NC=C(C2=CC=C(S(C(C)C)(=O)=O)C=C2)N=C1C1ON=C(C2=CC=C(CNC)C=C2)C=1 |
| | VE 822 Usage And Synthesis |
| Uses | 3-[3-[4-[(Methylamino)methyl]phenyl]-5-isoxazolyl]-5-[4-[(1-methylethyl)sulfonyl]phenyl]-2-pyrazinamine is a novel ATR (ATM-Rad3-related) inhibitor for in vitro and in vivo radiosensatization. | | Definition | ChEBI: 3-[3-[4-(methylaminomethyl)phenyl]-5-isoxazolyl]-5-(4-propan-2-ylsulfonylphenyl)-2-pyrazinamine is a sulfonamide. | | in vivo | PSN-1 xenografts are treated with Berzosertib (VE-822) (60 mk/kg; d0, 1), NSC 613327 (100 mg/kg; d0) and/or XRT (6 Gy; d1). Tumors are then harvested 2 h post-XRT. Berzosertib (VE-822) inhibits p-Ser-345-Chk1 in xenografts after DNA-damaging agents, establishing VE-822 as a potent inhibitor of ATR in vivo. Besides, Berzosertib (VE-822) enhances the therapeutic efficacy of radiation (XRT) in MiaPaCa-2 and PSN-1 xenograft models[1]. | | IC 50 | ATR: 0.2 nM (Ki); ATM: 34 nM (Ki); PI3Kγ: 220 nM (Ki) |
| | VE 822 Preparation Products And Raw materials |
|